Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
The ADDF supports promising, diverse international research projects to develop new drugs for Alzheimer's and related dementias, including vascular, Lewy body, and frontotemporal dementias, through 4 funding mechanisms: Drug Discovery, Program to Accelerate Clinical Trials (PACT), Neuroimaging and CSF Biomarker Development, and Prevention Beyond the Pipeline.
Característiques principals
FUNDING MECHANISMS:
  • Drug Discovery RFP: The goal of this RFP is to develop therapeutics for Alzheimer's disease and related dementias. This RFP focuses on building preclinical evidence in animal models and on advancing lead molecules to the clinical candidate selection stage. The proposed studies should have a high probability of reaching IND-enabling studies within two years.
  • Program to Accelerate Clinical Trials (PACT) RFP: The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. This includes novel, repurposed, and repositioned drugs as well as natural products.
  • Neuroimaging and CSF Biomarker Development RFP: The aim of this RFP is to develop biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias.
  • Prevention Beyond the Pipeline RFP: The RFP supports comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.
  • Lloc de presentació
    El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
    Servei de Recerca. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.05.76.
    Marta López: mlopez4@imim.es Ext.: 1576
    Carol Barnwell: cbarnwell@imim.es Ext.: 1670
    Convocatòria (URL)
    https://www.alzdiscovery.org/research-and-grants/funding-opportunities
    Dotació
  • Drug discovery: up to $600,000
  • Program to accelerate clinical trials : up to $3 million
  • Neuroimaging and CSF biomarker development program: up to $600,000
  • Prevention beyond the pipeline: $50,000-$100,000 (epidemiological analyses), up to $3 million for clinical trials
  • Durada
  • Drug discovery: 1 year, potential for follow-up funding
  • Program to accelerate clinical trials : multi-year, potential for follow-up funding
  • Neuroimaging and CSF biomarker development program: 1-2 years, potential for follow-up funding
  • Prevention beyond the pipeline: multi-year, potential for follow-up funding
  • AVÍS IMPORTANT
    Deadlines for 2020 RFPs:
    LETTERS OF INTENT:
  • January 17,
  • April 10
  • July 10
  • October 9
    INVITED FULL PROPOSALS:
  • February 7
  • May 8
  • August 7
  • November 6
  • Arxius

    Arxiu
    Funding Opportunities _ Alzheimer's Drug Discovery Foundation.pdf
    Drug Development Program _ Alzheimer's Drug Discovery Foundation.pdf
    Program to Accelerate Clinical Trials (PACT) _ Alzheimer's Drug Discovery Foundation.pdf
    Neuroimaging and CSF Biomarker Development Program _ Alzheimer's Drug Discovery Foundation.pdf
    Prevention Beyond the Pipeline _ Alzheimer's Drug Discovery Foundation.pdf
    Funding Opportunities_ Application & Funding Policies _ Alzheimer's Drug Discovery Foundation.pdf